Abingworth LLP

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
London
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ John Heard
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Abingworth LLP

Form 4 holding 10%+ Owner

SOLENO THERAPEUTICS INC

Security class
Common Stock
Shares / value
18,022,602
Estimated value
$657,560,041
Report date
29 Mar 2022
Price
$36.49
Ownership
Indirect
Form 4 holding 10%+ Owner

Sierra Oncology, Inc.

Security class
Common Stock, $0.001 par value
Shares / value
1,314,127
Estimated value
$72,276,985
Report date
31 Jan 2022
Price
$55.00
Ownership
Indirect
Form 4 holding 10%+ Owner

Vera Therapeutics, Inc.

Security class
Class A Common Stock
Shares / value
2,960,231
Estimated value
$53,284,158
Report date
18 May 2021
Price
$18.00
Ownership
Indirect
Form 4 holding 10%+ Owner

SOLENO THERAPEUTICS INC

Security class
Warrant (right to buy)
Shares / value
7,720,000
Estimated value
Report date
29 Mar 2022
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Jasper Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
78,045
Estimated value
Report date
21 Mar 2022
Price
Ownership
Indirect
Underlying class
Voting Common Stock
Underlying amount
Form 4 holding 10%+ Owner

eFFECTOR Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
40,000
Estimated value
Report date
06 Oct 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

SOLENO THERAPEUTICS INC

Security class
Stock Option (right to buy)
Shares / value
31,862
Estimated value
Report date
01 Jun 2021
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Vera Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
9,925
Estimated value
Report date
13 May 2021
Price
Ownership
Indirect
Underlying class
Class A Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Sierra Oncology, Inc.

Security class
Series B Warrants (right to buy)
Shares / value
0
Estimated value
Report date
28 Jan 2022
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Abingworth LLP

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .